Procurement Summary
Country: USA
Summary: Autoinjectors Containing Midazolam
Deadline: 23 Jul 2018
Posting Date: 09 Jul 2018
Other Information
Notice Type: Tender
TOT Ref.No.: 24800043
Document Ref. No.: W911QY-18-S-0009
Competition: ICB
Financier: Self Financed
Purchaser Ownership: -
Tender Value: Refer Document
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
The u.s. Army contracting command - aberdeen proving ground (acc-apg), natick contracting division intends to negotiate and award a firm fixed price, sole source contract to meridian medical technologies inc., located at 6350 stevens forest road, columbia, md 21046. Pursuant to the authority prescribed at 10 u.s.c. § 2304(c)(1) and federal acquisition regulation 6.302-1, only one responsible source and no other supplies or services will satisfy agency requirements. This acquisition requires the manufacture and delivery of 90, 000 food and drug administration approved autoinjectors containing the active ingredient midazolam. Meridian medical technologies (mmt) is currently under contract with the joint product management office - joint product manager - medical countermeasure systems (jpmo-jpm-mcs) for the development of an fda approved autoinjector for the treatment of seizures, under contract w9113m07-c-0159. This acat iii program was established by jpeo-cbrnd to develop an alternative treatment to replace the currently fielded cana autoinjector containing diazepam. The contract currently requires the delivery of initial operation capability (ioc) and full operational capability (foc) autoinjectors. This requirement increases the deliverable foc by 90, 000. Responders are encouraged to address their abilities to perform the requirements and accessibility to the necessary data within 15 days of this notice.
This is a modification to an existing contract. Mmt currently holds the investigational new drug application for an autoinjector containing the midazolam, and is under contract to obtain fda approval of a new drug application (nda). A determination by the government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the government.
This special notice is not a request for competitive proposals however, responsible parties purporting to have the necessary qualifications with the ability to meet this...
Documents
Tender Notice